Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Home  Sitemap  Imprint

GLSV news

30.01.2012 Global Life Science Ventures: 2011 Review more...

24.01.2011 Global Life Science Ventures: 2010 Review more...

14.01.2010 Global Life Science Ventures: 2009 Review more...

13.02.2009 Global Life Science Ventures: 2008 highlights more...

22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award" more...

14.04.2008 April 2008 Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene, Hanns-Peter Wiese, Venture Capial Magazin 4/2008 more...

17.01.2008 GLSV leads investment in Action Pharma A/S more...

06.12.2007 GLSV invests in Pelikan Technologies more...

02.10.2007 Biotech Investment Barometer Reveals Continued Confidence in Sector
more...

11.05.2007 NeurogesX Launches IPO on NASDAQ more...

More news

............................................................................................

Portfolio company news

05.12.2011 Zalicus Initiates Phase 1 Clinical Trial of Z160 more...

30.11.2011 USPTO upholds key Santaris Pharma A/S LNA patents in two re-examination cases brought by Isis Pharmaceuticals more...

29.11.2011 Horizon Pharma Announces U.S. Food and Drug Administration Acceptance of LODOTRA(R) New Drug Application for Review for the Treatment of Rheumatoid Arthritis more...

15.11.2011 Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference more...

14.11.2011 NeurogesX Receives FDA Acceptance for Review of sNDA for Qutenza(R) (capsaicin) 8% Patch for HIV-Associated Peripheral Neuropathy (HIV-PN)
more...

08.11.2011 NeurogesX Reports Positive Phase 2 Results for NGX-1998 for Treatment of Postherpetic Neuralgia more...

05.11.2011 Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients more...

19.10.2011 Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin Pipeline Development more...

19.10.2011 EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia more...

03.10.2011 Santaris Pharma A/S to report new clinical data from miravirsen Phase 2a study to treat Hepatitis C in late-breaking oral presentation at the AASLD 2011 annual meeting more...

More news